Beijing Indian Gleevec effect Indian Gleevec purchasing agent 13621079267

The effective rate of Gleevec in the treatment of newly diagnosed chronic myelogenous leukemia (C) exceeds 10%, and % of patients can achieve cytological remission. Gleevec (imatinib mesylate) is a new generation of targeted anti-cancer drug that inhibits platelet-derived growth factor receptor protein kinase. Gleevec is the most effective of all anti-tumor drugs.
Gleevec (imatinib mesylate) primary treatment disease classification:
Gleevec (imatinib mesylate) is used to treat newly diagnosed Philadelphia chromosome positive (+) of adult chronic myelogenous leukemia in the chronic phase.
Gleevec (imatinib mesylate) is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia in the blast phase and accelerated phase. Imatinib mesylate is also used to treat patients with interference with Chronic myelogenous leukemia in the chronic phase that has been treated with antibiotics.
Gleevec (imatinib mesylate) is also used to treat chronic myelogenous leukemia in children who have relapsed after bone marrow suppression or who have failed to respond to interferon therapy.
Gleevec (imatinib mesylate) is used to treat (C)-positive inoperable or metastatic malignant gastrointestinal stromal tumors.
For which patients is Gleevec effective? I have introduced it to you here. I believe you should be very clear about this issue after reading the description of the article. If there is anything unclear, you can consult the website. At the experts, they will give you a satisfactory answer.